NASDAQ:GLTO - Nasdaq - US36322Q2066 - Common Stock - Currency: USD
NASDAQ:GLTO (2/21/2025, 8:23:57 PM)
4.51
-0.33 (-6.82%)
The current stock price of GLTO is 4.51 USD. In the past month the price decreased by -18%. In the past year, price decreased by -72.81%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Galecto Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 13 full-time employees. The company went IPO on 2020-10-29. Galecto, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
GALECTO INC
75 State Street, Suite 100
Boston MASSACHUSETTS DK-2200 US
CEO: Hans T. Schambye
Employees: 13
Company Website: https://galecto.com/
Investor Relations: https://ir.galecto.com/
Phone: 14570705210
The current stock price of GLTO is 4.51 USD. The price decreased by -6.82% in the last trading session.
The exchange symbol of GALECTO INC is GLTO and it is listed on the Nasdaq exchange.
GLTO stock is listed on the Nasdaq exchange.
7 analysts have analysed GLTO and the average price target is 8.16 USD. This implies a price increase of 80.93% is expected in the next year compared to the current price of 4.51. Check the GALECTO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GALECTO INC (GLTO) has a market capitalization of 5.95M USD. This makes GLTO a Nano Cap stock.
GALECTO INC (GLTO) currently has 13 employees.
GALECTO INC (GLTO) has a resistance level at 4.79. Check the full technical report for a detailed analysis of GLTO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GLTO does not pay a dividend.
GALECTO INC (GLTO) will report earnings on 2025-03-06, after the market close.
GALECTO INC (GLTO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.39).
The outstanding short interest for GALECTO INC (GLTO) is 1.03% of its float. Check the ownership tab for more information on the GLTO short interest.
ChartMill assigns a fundamental rating of 2 / 10 to GLTO. While GLTO has a great health rating, there are worries on its profitability.
Over the last trailing twelve months GLTO reported a non-GAAP Earnings per Share(EPS) of -18.39. The EPS increased by 58.44% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -90.58% | ||
ROE | -101.14% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 86% to GLTO. The Buy consensus is the average rating of analysts ratings from 7 analysts.